Compugen

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees and has raised a total of $141.92 million across 7 funding rounds from 3 investors. The company went public on NASDAQ in August 2000 and on TASE in January 2002.

Business overview

Compugen is a clinical-stage drug-discovery and development company focused on immuno-oncology. The company leverages a predictive-discovery infrastructure to advance a therapeutic pipeline aimed at harnessing the immune system to eradicate cancer. Its pipeline is based on novel, Compugen-discovered immune checkpoint candidates designed to address unmet medical needs in various cancer types and patient populations, both as monotherapies and in combination. Compugen specializes in oncology and immunology, with an expanding focus on myeloid target candidates within the tumor microenvironment, operating within the Health Tech & Life Sciences sector.

Strategic signal

Compugen is actively engaged in presenting its research and clinical data at prominent scientific conferences, indicating ongoing progress and validation of its drug discovery efforts. In October 2025, the company is scheduled to present at SITC, and in September 2025, it will present research at the Single Cell Genomics Conference. These consistent presentations highlight Compugen's commitment to sharing scientific advancements and maintaining visibility within the immuno-oncology community, signaling continued development and potential future breakthroughs to investors.

Company Intelligence Q&A

What is Compugen's primary focus in drug discovery?

Compugen specializes in clinical-stage drug discovery and development, with a primary focus on immuno-oncology programs that utilize a predictive-discovery infrastructure to identify novel immune checkpoint candidates for cancer treatment.

When did Compugen go public on NASDAQ?

Compugen went public on NASDAQ in August 2000.

Which company invested in Compugen in October 2018?

In October 2018, Bristol-Myers Squibb Company invested in Compugen.

What was a significant intellectual property expansion for Compugen in October 2023?

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.

What recent clinical data will Compugen present at ESMO 2025?

In October 2025, Compugen is scheduled to present a pooled analysis of COM701 in three Phase 1 trials in patients with platinum-resistant ovarian cancer at ESMO 2025.